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Abstract
Objectives: Susceptibility to heroin dependence is strongly influenced by genetic factors with heritability
estimates as high as 0.7. A number of genes, as well as environmental factors, are likely to contribute to its
etiology. Not all individuals who have ever tried heroin at some stage during their lifetime become dependent
on heroin. It has been suggested that genetic factors might be more important in the transition stage to heroin
dependence rather than in environmental exposures and experimenting with heroin. As the features of
substance dependence and memory formation have been found to be strikingly similar, we have focused on a
key enzyme involved in long-term potentiation and synaptic plasticity, namely the calcium-dependent/
calmodulin-dependent protein kinase IIα (CAMKIIa). We hypothesized, that CamK2A genetic variation may
play a role in the transition from occasional to regular heroin use.
Materials and methods: Using quantitative trait association analysis, we addressed this hypothesis by
correlating the self-reported time interval between occasional and regular heroin use with the frequency of 12
single nucleotide polymorphisms located within the genomic region of the CamK2A gene. A sample of 570
Caucasian patients was available for analysis.
Results: Single marker association analysis (rs10066581, P=0.007), as well as haplotype analysis (global
P=0.005), suggested an association with the quantitative trait 'time interval from occasional to regular heroin
use.'
Conclusion: Our results propose that genetic variants located in the genomic region of the CamK2A gene
may be involved in transition time from occasional to regular heroin use.
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Susceptibility to heroin dependence is strongly influenced by genetic factors with heritability 26 
estimates as high as 0.7. A number of genes as well as environmental factors are likely to 27 
contribute to its aetiology. Not all individuals having ever tried heroin at some stage during their 28 
lifetime become dependent on heroin. It has been suggested that genetic factors might be more 29 
important in the transition stage to heroin dependence rather than in environmental exposures 30 
and experimenting with heroin. Since features of substance dependence and memory formation 31 
have been found to be strikingly similar, we have focused on a key enzyme involved in long 32 
term potentiation and synaptic plasticity, namely the calcium/calmodulin-dependent protein 33 
kinase II alpha (CAMKIIa). We hypothesized, that CamK2A genetic variation may play a role in 34 
transition from occasional to regular heroin use.  35 
Methods 36 
Using quantitative trait association analysis, we addressed this hypothesis by correlating the 37 
self-reported time interval between occasional and regular heroin use with the frequency of 12 38 
single nucleotide polymorphisms (SNPs) located within the genomic region of the CamK2A 39 
gene. A sample of 570 Caucasian patients was available for analysis.  40 
Results 41 
Single marker association analysis (rs10066581, P=0.007) as well as haplotype analysis (global 42 
P=0.005) suggested association with the quantitative trait ‘time interval from occasional to 43 
regular heroin use’.  44 
Conclusions 45 
Our results propose that genetic variants located in the genomic region of the CamK2A gene 46 







Heroin dependence 50 
























Heroin is a narcotic drug with a high potential to induce severe substance dependence. Results 71 
from the National Comorbidity Survey in US Adolescents indicated that the number of 72 
individuals who have started using heroin is continuously on the rise since 2007 (Substance 73 
Abuse and Mental Health Services Administration, 2014). Since heroin is regularly injected, 74 
there is a high risk of serious infectious diseases in users, such as hepatitis, or acquired 75 
immune deficiency syndrome, increasing the disease burden on individuals and society (Nutt et 76 
al., 2010).  77 
While heroin dependence and other substance dependence disorders are obviously driven by 78 
life style choices, genetic factors have been shown to play a substantial role in the aetiology as 79 
well (Merikangas et al., 1998; Tsuang et al., 1998). Heritability to heroin dependence is most 80 
likely multifactorial with a large number of susceptibility genes contributing to the aetiology. 81 
Notably, it has been suggested that environmental factors are more important for occasional 82 
drug use than for regular drug abuse and dependence (Kendler et al., 2003). In essence, drug 83 
dependence disorder is thought to be a multistep transition where initiation of drug use most 84 
likely is more influenced by environmental factors, whereas the transition from use to 85 
dependence may be more influenced by genetic factors. Therefore, we hypothesized that the 86 
investigation of genetic factors involved in transition from initial to regular (compulsory) heroin 87 
use may provide insights into the factors leading to heroin dependence.  88 
Genes involved in memory formation could possibly play a key role in this transition. Addiction 89 
and memory formation have been found to be strikingly similar in animal models. Both addiction 90 
and memory exert their main effects in similar brain regions including the hippocampus, 91 
amygdala, and the prefrontal cortex (Kelley, 2004; Koob and Volkow, 2010). In addition, 92 
molecular changes, such as changes in gene expression, in epigenetic regulation, as well as in 93 
synaptic plasticity and neuronal morphology are strikingly similar in addiction and in formation of 94 
memory (Hyman et al., 2006; Nestler, 2013). Thus, it is hypothesized that development of 95 
addiction could be related to a process of reward learning, leading to compulsive seeking, 96 





One key molecule involved in memory formation is the calcium/calmodulin dependent protein 98 
kinase (CaMKII), which is a serine/threonine protein kinase. The enzyme is an oligomeric 99 
protein, composed of distinct but related subunits encoded by separate genes. Function and 100 
dysfunction of CaMKII has been recently the subject of research in psychiatric disorders 101 
including addiction (Robison, 2014). CamK2A, the alpha isoform of CaMKII is a 102 
calcium/calmodulin - activated enzyme and is located on human chromosome 5q32. It has been 103 
mainly studied in chronic amphetamine and cocaine abuse, and more recently also in alcohol 104 
addiction (Muller et al., 2016; Robison, 2014). The enzyme is enriched in synapses and is 105 
thought to be a main component of the post synaptic density where it is bound to N-methyl-D-106 
aspartate-receptors (NMDAR). Interaction of CamK2A with the GluN2B subunit of the NMDAR 107 
seems to be crucial for synaptic strengthening and memory consolidation (Barria and Malinow, 108 
2005; Shipton and Paulsen, 2014). A mouse model, in which CaMKII binding to the NMDAR 109 
GluN2B subunit was impaired through introduction of two mutations in the GluN2B subunit 110 
showed deficits in early memory consolidation in the Morris water maze test, whereas the 111 
overall learning was quite normal. Thus it had been concluded that interaction of CaMKII with 112 
GluN2B might be important for the early phases of contextual memory consolidation and 113 
maintenance (Halt et al., 2012). 114 
 115 
 116 
We hypothesized, that genetic variation in CamK2A may play a role in transition from casual to 117 
regular and uncontrolled heroin use. We addressed this hypothesis by correlating the self-118 
reported time interval from first- to regular heroin use with the frequency of 12 single nucleotide 119 
polymorphisms (SNPs) located within the genomic region of the CamK2A gene. We had a 120 
sample of 684 Caucasian patients with heroin dependence available. We used quantitative trait 121 
association analysis for correlating the self-reported transition interval from first- to regular 122 








Materials and Methods 127 
 128 
Study sample 129 
Individuals with heroin dependence were identified by the Fresh Start Recovery Program in 130 
Perth, Australia, for the Western Australian Study on Heroin Dependence. The study was 131 
approved by the Human Research Ethics Committee of the University of Western Australia 132 
(RA/4/1/1814) and was carried out in accordance with the latest version of the Declaration of 133 
Helsinki (World Medical Association, 2013). Informed consent was obtained from each 134 
individual, and heroin dependence was confirmed using DSM-IV (American Psychiatric 135 
Association, 2000) criteria. Study participants were asked to complete a questionnaire, including 136 
questions on ethnicity, age at first use of heroin, years of overall use of heroin, time interval 137 
between occasional heroin use (less than once a week) and regular (i.e. daily) heroin use, 138 
previous treatment attempts and other legal and illegal drug use. All individuals underwent 139 
subsequent treatment with naltrexone implants within a research setting at the Fresh Start 140 
Recovery Program. Blood samples (anticoagulant EDTA), withdrawn during initiation for 141 
treatment, were used for DNA isolation, using standard procedures (Miller et al., 1988).  Before 142 





Genotyping of ancestry informative markers 148 
A total of 87 ancestry informative markers (AIMs) have been identified from Enoch et al., (2006) 149 
and genotyped at the Path West at the Department of Molecular Genetics, Perth, Australia 150 
using Illumina Golden Gate assay with multisample Sentrix® Array Matrix (Illumina, San Diego, 151 
CA, USA). Genotypes were called using the GenomeStudio Genotyping Module v1.0 software 152 
from Illumina. SNPs were excluded when Hardy-Weinberg equilibrium test revealed p<0.001, or 153 






Selection and genotyping of SNPs in the genomic region of the CamK2A gene 156 
The following criteria were used for selection of SNPs: (a) SNPs have to be relatively evenly 157 
distributed throughout the genomic region of the CamK2A gene, taking the block structure of the 158 
genomic region (identified using HaploView4.2 and 95% confidence intervals (Gabriel et al., 159 
2002)) into account; (b) SNPs with a minor allele frequency of >0.05 in Caucasian populations. 160 
A total number of 12 SNPs were selected (table 1). Genotyping was performed by either using 161 
self-designed PCR-RFLP assays, high-throughput fluorescence-based allelic discrimination 162 
assays (TaqMan SNP genotyping assay-by-demand Applied Biosystems, Foster City, CA, 163 
USA), or by using a self-designed high resolution melting (HRM) assay (table 1). All genotyping 164 
assays included between 50 and 70 samples in duplicate for quality control.  165 
TaqMan assays were performed according to the manufacturer’s instructions in 384-well 166 
microtiter plates containing in each well 5ng DNA, the locus specific primer set, and 5µl TaqMan 167 
mastermix as supplied by Applied Biosystems. The reaction mixture was amplified using an 168 
Applied Biosystems 7900 Real Time PCR system. Allele discrimination was done using the 169 
Sequence Detection Software v2.1 (Applied Biosystems, Foster City, CA, USA).  170 
Primers for PCR-RFLP assays were designed using the Primer3 Web software (Koressaar and 171 
Remm, 2007; Untergasser et al., 2012) and ordered from Eurofins MWG Operon, Ebersberg, 172 
Germany. PCRs were performed using 0.5µM of forward and reverse primer respectively 173 
(supplementary table 2), 12.5ng DNA, 200µM dNTPs, 1.25U Taq polymerase (Qiagen, Hilden, 174 
Germany), and 2µl buffer provided by Qiagen in a total volume of 20µl. Cycling conditions with 175 
annealing temperatures as outlined in supplementary table 2 were 5 minutes denaturation at 176 
95°C followed by 30 cycles, each cycle consisting of 30 seconds denaturation at 95°C, 40 177 
seconds annealing, and 60 seconds elongation at 72°C. A final extension step was included 178 
consisting of 10 minutes at 72°C. Restriction enzymes were purchased from New England 179 
Biolabs, Frankfurt/Main, Germany, and digestion was performed by adding 0.5µl buffer 180 
(supplied by the manufacturer), 5U of specific enzyme (supplementary table 2), in a total 181 
volume of 20µl. The mixture was incubated for 3 hours at 37°C. Electrophoresis of the digested 182 
product was performed after application to a gel containing 2.5% agarose. Digested products 183 





were also developed for TaqMan assays with less than 95% genotyping completeness (table 1). 185 
For quality control and genotyping consistency, duplicated samples, comprising samples with 186 
known genotype, were included in these assays.  187 
For SNP rs10463293, we developed a HRM assay for allele discrimination. Primer3 Web 188 
software (Koressaar and Remm, 2007; Untergasser et al., 2012) was used for selection of 189 
primers (supplementary table 2), and the DINAMELT web server (Markham and Zuker, 2005) 190 
was used for analysing the suitability of the PCR product for HRM analysis. Primers were 191 
synthesized by Eurofins MWG Operon, Ebersberg, Germany.  PCR reactions were performed in 192 
10µl, containing 0.7µM forward and 0.7µM reverse primer, 10ng DNA, and Type-it HRM master 193 
mix (Qiagen, Hilden, Germany) according to the manufacturer’s recommendations. Cycling 194 
conditions, using a Roche Lightcycler480 were as follows: 5 minutes denaturation at 95°C 195 
followed by 45 cycles, each cycle consisting of 10 seconds denaturation at 95°C, 30 seconds 196 
annealing / elongation at 57°C. Subsequent high resolution melting curve analysis was 197 
performed by heating to 65°C for 1 second, followed by continuous heating up to 95°C with a 198 
ramping rate of 0.02°C /second and 25 data acquisition points per second. After this, samples 199 
were cooled to 40°C. The Roche Lightcycler480 Gene Scanning module was used for allele 200 
discrimination. Genotypes were allocated according to four reference samples, which had been 201 
sequenced using BigDye chemistry (Applied Biosystems) for allele identification.   202 
 203 
Quality control 204 
Quality control was based on genotyping information from ancestry informative markers 205 
(supplementary table 1) as well as on genotyping information for 12 locus specific markers 206 
(table 1). Three samples were deleted due to failing genotyping completeness (<0.9 in the 87 207 
ancestry informative markers). In order to confirm the ethnic background Eigenstrat analysis 208 
was applied. Study participants (N=4), with >6 standard deviations outside of the mean for 209 
eigenvector 1 or eigenvector 2 were deleted. In addition, we applied the pairwise identity by 210 
decent information tool in PLINK in order to control for related or duplicated samples, which 211 





parameters was available. The final sample consisted of 684 study participants (450 male and 213 
234 female).  214 
 215 
Statistical Methods 216 
Genome Studio Genotyping Module v1.0 (Illumina) was used to analyse ancestry informative 217 
SNPs.  SNPs with a GenTrain score of <0.6, a genotyping completeness of <0.9, and 218 
HWE<0.001 were excluded. Single samples were excluded for further analysis when 219 
genotyping completeness across the SNPs was <0.9.  220 
The program Eigenstrat (Price et al., 2006) was used for analysis of ancestral background and 221 
identification of ethnic outliers. For this purpose, genotype information was extracted for 222 
samples from the Hapmap database for the CEPH population (CEU) N=174, the Chinese 223 
population Beijing (CHB) N=86, and the Yoruba in Ibadan, Nigeria (YRI) N=175. 224 
PLINK (Purcell et al., 2007) was used for analysis of quantitative phenotypes and genotypes, 225 
generating p-values, which are based on a Wald test. Since ethnic outliers had been removed 226 
prior to this analysis, no further covariates were used. In addition, we used the pairwise IBD 227 
detection tool implemented in PLINK for identification of close relationships between individuals. 228 
Haploview 4.2 (Barrett et al., 2005) was used for identification of the LD block structure with 229 
95% confidence intervals (Gabriel et al., 2002) (figure 1).  230 
Analysis of haplotypes was completed using FAMHAP (Becker and Knapp, 2004a; Becker and 231 
















Phenotypic parameters 244 
Table 2 provides further details for phenotypic characterization. Data on phenotypic 245 
characterization was available for 68% to 95% of the sample, pending on the parameter 246 
considered. Most of the individuals started using heroin in early to late adolescence. The 247 
average self-reported age of initiating heroin use was 19.6. More than 75% of them have been 248 
using heroin >5 years.  More than half of the individuals (53%) reported no time delay between 249 
occasional and regular heroin (figure 2). Abuse of other illegal drugs was commonly reported. 250 
Moreover, most of the study participants had two or more treatment attempts for heroin use 251 
dependence in the past.  252 
 253 
Analysis using quantitative phenotype ‘time interval from occasional to regular heroin use’ 254 
A total of 570 individuals were available for this phenotype. Three markers, rs4958468, 255 
rs10066581 and rs6869634 revealed nominal statistically significant p-values (p=0.03, p=0.007 256 
and p=0.018 respectively) with the quantitative trait ‘time interval from occasional to regular 257 
heroin use’ (table 3, supplementary table 3 for gender specific analysis). None of these p-values 258 
survives multiple testing. Due to the small number of homozygote minor allele genotypic carriers 259 
(N=3), the nominally significant association for rs4958468 was not considered to be informative. 260 
For rs10066581 (table 3), minor allele carriers showed a longer ‘time interval from occasional to 261 
regular heroin use’ (4.09 and 2.18 years for homozygote and heterozygote minor allele carriers, 262 
respectively). In contrast, for rs6869634, carriers of the major allele showed association with a 263 
longer time interval (2.04 and 1.44 years for homozygote and heterozygote major allele carriers, 264 
respectively) (table 3). Since rs10066581 and rs6869634 are located in the same haplotype 265 
block (figure 1), we investigated whether haplotype analysis could support the nominal 266 
association of minor and major allele in the same haplotype block.  267 
We performed haplotype trend regression as implemented in FAMHAP for an overall estimation 268 
of association of haplotypes based on markers located in LD block 2 (block 2: rs10066581 and 269 





that none of the marker combinations tested is associated, was produced. In order to obtain 271 
more information on the nature of this association, we extracted haplotypes which were 272 
generated by FAMHAP based on the expectation-maximization algorithm. Only haplotypes with 273 
a frequency of >0.01 and a likelihood weight >0.99 were included in this post hoc, exploratory 274 
analysis. Our investigation focused on carriers of haplotype ‘3’, composed of the minor allele for 275 
rs10066581 and the major allele for rs6869634, since this allele combination was implicated by 276 
initial analysis in PLINK. Descriptive statistics (table 4) revealed a longer ‘time interval from 277 
occasional to regular heroin use’ for carriers of haplotype ‘3’ with an average of 2.32 years. In 278 



























In the present paper we describe investigation of a possible influence of genetic variants in the 302 
gene for CamK2A on the ‘time interval from occasional to regular heroin use’ using quantitative 303 
trait analysis. The main finding of our study was the nominal association of the minor allele of 304 
SNP rs10066581 (A-allele) with a longer ‘time interval from occasional to regular heroin use’. As 305 
a quantitative phenotype we used a self - reported parameter, namely the elapsed time between 306 
occasional- and regular heroin use. Thus, in contrast to the classical case/control design, where 307 
only the end point of heroin use is considered, we accounted for the multi-staged process from 308 
initiation of heroin use to heroin dependence. We hypothesized, that this design should enable 309 
us to identify genetic factors underlying the transition from exposure to addiction.  310 
  311 
Heroin dependence might have common features with other drug dependence disorders. For 312 
example, the multi-staged process leading to dependence has been investigated in more detail 313 
for nicotine dependence. Here, it has been shown that genetic factors are important in the 314 
transition stage from initial use to drug dependence (Sullivan and Kendler, 1999). Similar data 315 
has been reported for cannabis use (Agrawal and Lynskey, 2006), as well as in a study of 316 
initiation and subsequent abuse of illicit drugs in women (Kendler et al., 1999). In addition, a 317 
series of twin studies for alcohol- and nicotine dependence (Stallings et al., 1999), and for illicit 318 
drugs, including heroin (Tsuang et al., 1998) suggested, that genetic factors could be more 319 
important in transition than in initiation of drugs of abuse.  320 
 321 
A number of quality controls were used in order to assure confidence in the reported results. 322 
Firstly, genotyping included about 10% of duplicated samples. No discrepancies in genotypes 323 
were detected. Secondly, we used ancestry informative markers in an attempt to confirm the 324 
self - reported ethnicity. This is important to avoid biased results due to population caused 325 
variation of allele frequencies. Thirdly, we used the ancestry informative markers for detection of 326 
hidden relationship between study participants, which may bias allele and genotype 327 





Even though the number of ancestry informative markers was low, we could make adjustments 329 
regarding ethnic homogeneity of the sample, as well as regarding independence of individuals. 330 
However, for a more accurate estimation of ethnic differences in allele frequencies, and for 331 
identification of the descent status for detection of hidden relationship, more than 100,000 332 
genetic variants would have been necessary (Purcell et al., 2007).  333 
 334 
Limitations of our approach are related to the phenotype which is based on self – reporting. 335 
While all of our study participants were diagnosed with heroin dependence using diagnostic 336 
guidelines (DSM-IV), we have not been able to corroborate the time point of onset of heroin 337 
dependence using the diagnostic manual, nor were we able to independently confirm the time 338 
point of first use of heroin. This may have confounded the quantitative phenotype. In addition, 339 
quantitative data was not normally distributed. When deleting samples with a reported 340 
occasional to regular heroin use of more than 5 years (i.e. outliers based on the distribution of 341 
data), p-values increased and only rs4958468 (p=0.03) was still nominally significant, whereas 342 
rs10066581 showed a marginal significant p-value of 0.06. The increase in p-values may be 343 
due to the reduced power of the sample (N=515). 344 
 345 
We focused our analysis on the gene encoding the enzyme calcium/calmodulin dependent 346 
protein kinase 2A (CamK2A), which had been reported to be linked to learning and memory. 347 
This enzyme is involved in hippocampal long term potentiation and spatial learning (Colbran 348 
and Brown, 2004). There is some support from animal models for involvement of CamKII in drug 349 
dependence. It has been shown, that induced morphine sensitization modulated the mRNA 350 
expression of CaMKII in the hippocampus of rats (Kadivar et al., 2014). Moreover, CamK2A had 351 
been implicated in cocaine dependence before (Easton et al., 2014). It had been shown that 352 
carriers of an intronic variant located within this gene (rs3776823-TT) undergo a faster transition 353 
to severe cocaine use. We were unable to show an influence of this specific variant in our study. 354 
However, we found a shorter self-reported time interval between occasional- and regular heroin 355 





upstream of rs3776823 in intron 15 of the CamK2A gene. These findings suggest that transition 357 
time may be influenced by genetic variants in this gene. 358 
 359 
We have used PLINK for single marker association analysis using a quantitative parameter. 360 
Taking the linkage disequilibrium block structure of the genomic region into account, we have 361 
explored the relationship between haplotypes and the time interval between occasional- and 362 
regular heroin use with the program FAMHHAP (Becker and Knapp, 2004a; Herold and Becker, 363 
2009). Haplotype trend regression for quantitative traits and 10,000 permutations, implemented 364 
in FAMHAP yielded corrected p-values against the global null hypothesis that none of the 365 
marker combinations is associated with the phenotype. Explorative descriptive statistics using 366 
haplotype frequencies as estimated in FAMHAP (Becker and Knapp, 2004b), revealed further 367 
support for results obtained with PLINK.  368 
 369 
No function for variant rs10066581 has been reported in current databases. We used RegRNA 370 
v2.0 (Huang et al., 2006) in order to identify possible relevant regulatory RNA motifs. We found 371 
the G-allele of rs10066581 as a transcriptional regulatory motif. Specifically, it serves as binding 372 
site for the transcriptional enhancer C/EBPdelta. Presence of this intronic transcriptional 373 
enhancer motif may be important in fine tuning the transcriptional activity of CAMK2A, impacting 374 
synaptic plasticity. Homozygote carriers of the G-allele for this specific polymorphism revealed 375 
on average a shorter transition time to regular heroin use (1.6 years) versus carriers of the A-376 
allele (4.1 years), which may support the idea that a stronger transcription of CamK2A may 377 
strengthen memory formation earlier or faster.  Further experiments and analyses are 378 
necessary to support or refute this hypothesis. 379 
 380 
In conclusion, in this study we focused on a sub-phenotype of heroin dependence, time interval 381 
between occasional- and regular heroin use, where genetic factors might play a substantial role. 382 
To address this, we performed quantitative trait analysis. Our results suggest that variants 383 
located in the CamK2A gene may contribute to transition from occasional to regular heroin use. 384 
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Figure 1: Linkage disequilibrium block structure generated using Haploview 4.2 and confidence 521 
intervals 522 
Figure 2: Histogram showing the distribution of time for the quantitative parameter time interval 523 
from occasional to regular heroin use in years 524 
Table 1: Characteristics of SNPs including genotyping information 
 
  




locationa  Exon/Intron Polymorphism 
Minor 





in cases (%) 
rs2241694 149,602,608 Exon 18 G/A A 0.086 0.104 0.097 PCR-RFLP 0.19 94.2 
rs4958468 149,605,211 Intron 17 C/T T 0.086 0.104 0.099 TaqMan 0.31 94.8 
rs10051644 149,606,748 Intron 17 T/C C 0.379 0.313 0.288 TaqMan 0.90 97.5 
rs10066581 149,615,681 Intron15 G/A A 0.197 0.126 0.163 TaqMan 0.15 96.3 
rs6869634 149,616,719 Intron 15 G/A A 0.246 0.214 0.179 TaqMan, PCR-RFLP 0.42 98.3 
rs2288799 149,631,413 Intron 8 A/G G 0.480 0.423 0.444 TaqMan 0.31 95.3 
rs10463293 149,636,073 Intron 5 T/G G 0.470 0.429 0.444 HRM 0.74 95.5 
rs3776823 149,637,605 Intron 3 C/T T 0.333 0.269 0.280 PCR-RFLP 0.37 99.2 
rs3822606 149,641,155 Intron 3 C/T T 0.333 0.264 0.284 TaqMan, PCR-RFLP 0.35 97.9 
rs34087853 149,657,367 Intron 1 A/G G 0.192 0.242 0.228 TaqMan 0.47 97.0 
rs6894342 149,659,180 Intron 1 C/T T 0.091 0.159 0.122 TaqMan 0.14 98.0 
rs10050608 149,660,949 Intron 1 G/C C 0.177 0.181 0.223 TaqMan 0.72 95.3 
 
a Genomic location in basepairs NCBI Version GRCh37.p5 (37.3) 
b Minor allele frequency as reported in 1000 Genomes Project, phase 3, version 3.7 for the CEU (Utah population) and the British (in England and Scotland) 
population 
c N=  570 cases with information on time interval between occasional - and regular use of heroin 
d TaqMan: Fluorescence based allelic discrimination assays based on TaqMan technology; PCR-RFLP: PCR amplification followed by restriction enzyme digestion 
for allele discrimination; HRM: high resolution melting 
e HWE: p-value for Hardy Weinberg equilibrium test 





Range Quartile 1 
to Quartile 3 
Age at first use 651 (425/226) 19.63 5.82 16-22 
Years of overall use 612 (409/203) 11.5 7.33 5-15 
Years between occasional and regular use 570 (375/195) 1.81 3.31 0-2 
Number of additional illegal drugs used 
along with heroin 
466 (293/173) 1.59 0.79  
 
Table 3: Quantitative association using PLINK (Wald test) for occasional to regular heroin use 
SNPa BETA (regression coefficient) T (Wald test) P-value Genotypes b Counts c frequency mean (years)d 
rs2241694 0.5336 1.487 0.1376 2/2 2 0.003745 2 
    2/1 100 0.1873 2.29 
    1/1 432 0.809 1.721 
rs4958468 0.7277 2.099 0.0362 2/2 3 0.005545 1.333 
    2/1 102 0.1885 2.51 
    1/1 436 0.8059 1.664 
rs10051644 -0.2354 -1.076 0.2825 2/2 49 0.08845 2.112 
    2/1 221 0.3989 1.484 
    1/1 284 0.5126 2.088 
rs10066581 0.7450 2.694 0.0073 2/2 11 0.01986 4.091 
    2/1 159 0.287 2.182 
    1/1 384 0.6931 1.608 
rs6869634 -0.6007 -2.371 0.0181 2/2 21 0.03743 0.8333 
    2/1 159 0.2834 1.44 
    1/1 381 0.6791 2.039 
rs2288799 0.0013 0.006 0.9951     
rs10463293 0.0349 0.171 0.8645     
rs3776823 0.1211 0.541 0.5883     
rs3822606 0.2089 0.936 0.3495     
rs34087853 0.1210 0.498 0.6186     
rs6894342 -0.3696 -1.185 0.2365     
rs10050608 0.1302 0.548 0.5837     
a SNPs in bold indicate statistically significant results obtained 
b “2” indicates minor allele, “1” indicates major allele 
c count of individuals 
d mean of self-reported time between occasional and regular use of heroin in years  
 
Table 4: Descriptive statistics for sample with haplotypes extracted from FamHap for rs10066581 – 
rs6869634. Samples were grouped according to presence / absence of haplotype 3 (composed of 
minor allele “A” for rs10066581 and major allele “G” for rs6869634) 
 
 Haplotype 3 absent Haplotype 3 present 
Individuals N 381 167 
Frequency 0.695 0.305 
Range for 'time interval from 
occasional to regular drug use' in 
years 
0 - 17 0 - 23 
Mean for 'time interval from 
occasional to regular drug use' in 
years 
1.61 2.32 
Standard Deviation 3.022 3.964 
















Time in years between occasional and regular heroin use
 





1 2795967 rs3100865 1 
1 92584784 rs12125484 0.6492 
1 106571633 rs6687440 0.0795 
1 161681183 rs4265409 0.5747 
2 4863959 rs934993 0.4463 
2 5257953 rs6718709 0.4375 
2 33017154 rs12618959 0.4262 
3 57215650 rs1028040 0.1953 
3 66984977 rs1373340 1 
3 106241722 rs1503079 0.655 
3 109082643 rs10933921 0.3102 
3 112365016 rs6414248 0.7321 
3 118667838 rs1698042 1 
3 130747960 rs2625956 0.9547 
3 137062756 rs1519260 0.9378 
3 190104562 rs4687002 0.054 
4 6010036 rs733370 0.2259 
4 26870541 rs1488299 0.1727 
4 41651170 rs1507086 0.4057 
4 81106993 rs11098964 0.7501 
4 82602473 rs1444893 0.9949 
4 89234881 rs2231164 0.7906 
4 144611612 rs1397529 0.4259 





4 159827612 rs12644851 0.7026 
4 178348998 rs6552216 0.9405 
5 4958892 rs26880 0.8452 
5 5633216 rs246760 0.8261 
5 116167937 rs2937067 0.8318 
5 117895090 rs6595142 0.7477 
5 152940571 rs4958667 0.9763 
6 5677819 rs6926774 0.4266 
6 71295098 rs2842063 0.1779 
6 127005719 rs1538956 0.6659 
6 132739275 rs9388989 0.5002 
6 135648258 rs1052502 0.6506 
7 15202657 rs4721415 0.5413 
7 98812524 rs6955490 0.2309 
7 112928544 rs953023 0.6774 
7 142552081 rs315280 0.6406 
8 4767247 rs11136793 0.7118 
8 16833064 rs12678324 0.8213 
8 53063166 rs2102727 0.4816 
8 66633516 rs6991838 0.529 
8 68994970 rs6472362 0.3844 
8 93173981 rs1552314 0.7743 
8 132834923 rs1514626 0.2755 
8 134925795 rs10113320 1 
9 8149670 rs721905 0.6747 
9 9720381 rs2225979 0.8945 
9 17504515 rs1885167 1 





9 109995109 rs556399 0.0035 
9 111651570 rs2004426 0.0728 
9 126307510 rs3814134 1 
10 8126176 rs10795588 0.7669 
10 23551932 rs958425 0.1167 
10 33876047 rs1869237 0.4287 
10 55283129 rs10763013 0.5001 
10 90906065 rs11203006 0.5951 
10 107333364 rs10884188 0.9901 
10 108849094 rs1336978 0.0725 
10 127879147 rs2930125 0.1405 
12 11592755 rs2416791 0.5843 
12 78632547 rs711159 1 
12 110021205 rs1001484 1 
12 110436233 rs628825 0.037 
12 125546608 rs10847171 0.5173 
13 39593992 rs915286 0.0473 
13 71204246 rs9318026 1 
14 31240826 rs4981115 0.8698 
14 76914874 rs2193595 0.9931 
14 97241370 rs1003229 0.7519 
15 46047011 rs2934193 0.9028 
15 61582014 rs289816 0.5124 
15 90062853 rs6496858 0.727 
16 30364851 rs4787645 0.688 
16 30730548 rs4889490 0.5361 
16 31045213 rs889548 0.6256 





19 55829472 rs2387137 0.8555 
20 30608468 rs6141319 0.5801 
20 52625318 rs6023367 0.0725 
20 57451501 rs12481662 0.1365 
20 59414462 rs6061779 0.3582 
20 61629948 rs310644 0.6812 
22 25122236 rs650276 0.3724 
 
Supplementary table 2: Details for self-designed allele discrimination assays  
      CAMK2A 
SNP Primer sequence Annealing temperature Restricition enzyme 
Size of PCR 
product Size and alleles for digested products 
rs2241694 F: GGCAACACTCCCATCCTTTA 60°C BccI 242 bp G-Allele (1): 19+211+12 bp 
 
R: ATCCCCACATCCACCTGAT 
   
A-Allele (2): 19+99+112+12 bp 
rs6869634a F: ATGACCAGGAAGGGACACAC 62°C AciI 217 bp G-Allele (1): 26+191 bp 
 
R: GTTGACCTCGAGGGAACTCA 
   
A-Allele (2): 217 bp 
rs3776823 F: CCTCAGACTTGGGAGCAGAG 57°C Cac8I 219 bp C-Allele (1): 27+62+130 bp 
 
R: CCAAGTCATGGAAAGCCTGT 
   
T-Allele (2): 62+157 bp 
rs3822606a F: TCTGACTCCAGAGCCCTTGT 55°C Hpy188I 174 bp C-Allele (1): 135+39 bp 
 
R: TGGCTTGATTCATGCACTTC 
   
T-Allele (2): 174 bp 
rs10463293b F: TAATCTCACCCACCCCACCT 57°C  N/A 96 bp N/A 
 
R: CTCTCCTCTGCACGTCCCTA 
    
      a  replication with RFLP for genotyping completeness and confirmation of genotypes 
  b using high resolution melting for genotyping 
    
